IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Peter Emig et al.

GAU 1624 Examiner Kahsay Habte

Serial No. 09/910,141

Filed on July 10, 2001

For: NOVEL HETEROARYL DERIVATIVES, etc.

Attorney's Docket 0691-070

Commissioner of Patents Washington DC 20231

Sir:

Information Disclosaure Statement

Enclosed herewith is an Information Disclosure Statement Form, together with a copy of each of the references identified therein.

WO 99/16751 relates to benzamidine derivatives foir inhibiting the Xa coagulation factor for treatment and prophylaxis of thromboebolytic diseases.

European patent No. 112,776 relates to naphthalene and azanaphthalenecarboxamidem derivatives and methods for making.

European patent No. 831,090 relates to N-substituted cyclic amines, methods for making, and compositions containing them.

Customer No. address 23622

Gabriel R. Katona, attorney of record

Respectfully submitted

It is hereby certified that this is being mailed on November 13, 2002

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB

Complete if Known Substitute for form 1449A/PTO **Application Number** 09/910.141 INFORMATION DISCLOSURE July 10, 2001 Filing Date Peter Emia et al. STATEMENT BY APPLICANT First Named Inventor 1624 Art Unit (use as many sheets as necessary) Kahsay Habte Examiner Name 0691-070 Attorney Docket Number of Sheet

			U.S. PATE	NT DOCUMENTS	
Examiner Initials		Document Number Number- Kind Code ³ (il known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 5,432,175	07-11-1995	Piwinski et al.	
		us- 5,861,395	01-19-1999	Taveras et al.	
		US-			
		US-			
-,		us-	na an Managa ny inana any akaominina na amin'ny fivondronan-		
	<u></u>	US-			
		US-			
		Us-			
		US-		nga paganan ang mang mang mang mga ng pagangan ngang paganan nganggan ngan mga pagan ngan nganggan na sahanga kanang kanang	
	L	US-			
	L	US-			
		US-			
	ļ	US-			and the second s
		<u> US-</u>			
·		US-			
	<u> </u>	US-			
		US-			and the same of th
	ļ	US-			
	 	US-			
		US-		l	

FOREIGN PATENT DOCUMENTS									
Examiner Initiais	Cite No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 4 (f known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Ţ6			
		WO 97/44329	11-27-1997						
		WO 99/16751	04-08-1999						
		WO 00/12074	03-09-2000						
		WO 00/51614	09-08-2000						
		EP 0 112 776 A2	07-04-1984		agrammer and the second of				
		EP 0 831 090 A1	03-25-1998	_					
						<u> </u>			
			Anna and 18 11 12 1 18 1 18 1 18 1 18 1 18 1 18						
					-				
	1	'	ĺ						

	 the state of the s	
Examiner	Date	
Signature	Considered	
Oignature	CONTORORIO	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PAPICATION of the religion to the support of the temperar must be serviced by the solution of the patient document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patient document, the indication of the year of the reign of the Emperar must precede the serial number of the patient document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 4 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. control number.

Substitute for form 1449B/PTO	Complete If Known		
	Application Number	09/910.141	
INFORMATION DISCLOSURE	Filing Date	July 10, 2001	
STATEMENT BY APPLICANT		Peter Emia et al.	
STATEMENT OF APPLICANT	Group Art Unit	1624	
(use as many sheets as necessary)	Examiner Name	Kahsay Habte	
Sheet 2 of 2	Attorney Docket Number	0691-070	

		OTHER PRIOR ART NON PATENT LITERAL		_			
Examiner Initials	Cite No. ⁵	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), nuhlisher, city and/or country where published					
e		TODD R. ELWORTHY, ANTHONY P.D.W. FORD, N-Arylpiperazinyi-N'-propylamino Derivatives of He Uroselective a1-Adrenoceptor Antagaonists, J. Med	GARY W. BANTLE, et al., teroaryl Amides as Functional d. Chem. 1997, 40 , 2674-2687				
		ARTHUR G. TAVERAS, JEFF DESKUS, JIANPING al., Identification of Pharmacokinetically Stable 3,10-Dibrome-8-chlorobenzocyclohaptapyridine Fa	mesyl Protein Transferase Inhibitors				
٠.		with Potent Enzyme and Cellular Activities, J. Med	Chem. 1999, 42, 2651-2661				
del amort relace i se relace e carbo		EL-SEBALA. IBRAHIM, I. CHAABAN and S. M. EL Quinoline Derivatives of Potential Antiameblc Activ 155-156	-KHAWASS, Synthesis of Some lty, Pharmazie 32, H. 3 (1977),	_			
Againmen This About symmetry	<u> </u>			-			
÷	1						

1	Examiner		Date	
l	Signature		Considered	
E)	KAMINER: Initial	if reference considered, whether or not citation is in conformance with MPI	EP 609. Draw Ilne	a through citation if not in conformant

and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO **Application Number** 09/910.141 INFORMATION DISCLOSURE July 10, 2001 Filing Date Peter Emia et al. First Named Inventor STATEMENT BY APPLICANT 1624 Art Unit (use as many sheets as necessary) Kahsay Habte Examiner Name 0691-070 **Attorney Docket Number** of Sheet

		• .	U.S. PATI	ENT DOCUMENTS	an/sipolar
Examiner Cite		Document Number Number - Kind Code ² (If known	Publication Date Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KI		US- 5,432,175 US- 5,861,395	07-11-1995 01-19-1999	Piwinski et al. 5/4/ Taveras et al.	1252
		US-		57	
		US-	-		BECEIVE
		US-		A CONTRACTOR OF THE CONTRACTOR	
		US-			NOV 2 0 20d2
	 .	US-		The state of the s	
		US-			TECH CENTER 1600/290
		US-		AND	
		us-		The street programme and the street with the street of the street with	
	╁	US- I U8-		m man man man man and a set appeal do the property of the set of t	
	<u> </u>	us-		The second secon	
	╂	US-		The state of the s	
		US-			
		US-		<u> </u>	

FOREIGN PATENT DOCUMENTS							
Exeminer Initials	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁴ (* known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆	
Y.		WO 97/44329	11-27-1997				
		WO 99/16751	04-08-1999		CONTRACT OF A STATE OF THE PARTY OF THE PART		
		WO 00/12074	03-09-2000	and the second second second second second			
		WO 00/51614	09-08-2000	se time en el communicación de la communicación de la communicación de la communicación de la communicación de	·		
		EP 0 112 776 A2	07-04-1984	e programa de la compansión de la compan	man a comment		
	******	EP 0 831 090 A1	03-25-1998	and the second s			
		A STATE OF THE RESIDENCE OF THE PROPERTY OF TH		· · · · · · · · · · · · · · · · · · ·			
		and the second s					
		The same of the sa			the state of the territory of the state of t		

Examiner Signature	they lask	-	Date Considered	June 12,2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in

*EXAMINER: Initial if reterence considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Engilst rengiouse translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it centains a valid OMB control number.

Complete if Known Substitute for form 14498/PTO 09/910.141 **Application Number** INFORMATION DISCLOSURE July 10, 2001 Filing Date Peter Emia et al. First Named Inventor STATEMENT BY APPLICANT 1624 Group Art Unit Kahsay Habte (use as many sheets as necessary) **Examiner Name** 0691-070 Attorney Docket Number of 2

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
KI		TODD R. ELWORTHY, ANTHONY P.D.W. FORD, GARY W. BANTLE, et al., N-Arylpiperazinyi-N'-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective a1-Adrenoceptor Antagaonists, J. Med. Chem. 1997, 40, 2674-2687				
K٩		ARTHUR G. TAVERAS, JEFF DESKUS, JIANPING CHAO, CYNTHIA J. CACCARO, et al., Identification of Pharmacokinetically Stable 3,10-Dibromo-8-chlorobenzocycloheptapyridine Farnesyl Protein Transferase Inhibitors with Potent Enzyme and Cellular Activities, J. Med Chem. 1999, 42, 2651-2661				
			١.			
KN		EL-SEBALA. IBRAHIM, I. CHAABAN and S. M. EL-KHAWASS, Synthesis of Some Quinoline Derivatives of Potential Antiamebic Activity, Pharmazie 32, H. 3 (1977), 155-156				
		RECEIVED				
ens, lawry might is any missianann m		NOV 2 0 2002				
p		TECH CENTER 1600/2900				
**************************************		The state of the s	-			
		*				
			丄			

Examiner Aff (M)	(hbx	Date Considered	June	18,2003

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.